Omid Dardashti, MD
- Specialties
-
CardiologyNuclear CardiologyEchocardiography
- Gender
-
Male
- Languages
-
SpanishHebrew
Location(s)
VMG - Cardiology, Ridgewood
1200 E. Ridgewood Ave
Suite 304 East
Ridgewood, NJ 07450
Phone: 201-689-9400
Fax: 201-689-9404
Education
- Education
-
MD, Rutgers University, Piscataway Campus, 1997 - 2001
BA, Rutgers University, 1992 - 1996
- Fellowships
-
St. Vincent's Hospital And Medical Center, Cardiovascular Diseases, 2004 - 2007
- Internship & Residency
-
Robert Wood Johnson University Hospital, Internal Medicine, 2001 - 2004
- Board Certifications
-
American Board Of Internal Medicine - Certified, 2004
Subspecialty Board Of Cardiovascular Disease - Certified, 2007
The Certification Board Of Nuclear Cardiology - Certified, 2006
Get to Know Me
What are some of the specific conditions you treat?
Congestive heart failure, hypertension (high blood pressure), coronary artery disease, rhythm disorders, valvular heart disease.
What techniques or procedures do you use in your practice?
Exercise stress testing, nuclear imaging, ultrasound/echocardiography, including transesophageal.
What would you like patients to know about your approach to care?
I take pride in providing compassionate, personalized care to the adult cardiology patient, and making him or her feel comfortable with me as I address his or her needs.
Awards & Accolades
Castle Connolly Top Doctor New York Metro Area
Castle Connolly
2014-2015
Inside Jersey Magazine Top Doctors
Inside Jersey Magazine
2014-2015
Publications & Research
Publications
Epicardial Surgical Ligation of the Left Atrial Appendage Is Safe, Reproducible, and Effective by Transesophageal Echocardiographic Follow-up
Innovations
2013
Oncology Research
The Amino Terminus of Cdk2 Binds p21
1996
Clinical Trials
Pfizer 22 and Pfizer 38
LATITUDE
Tests whether losmapimod, a new anti-inflammatory medication, can safely reduce the risk of a subsequent cardiovascular event (such as death, heart attack, or near heart attack requiring urgent treatment ) when started immediately after a heart attack.
GLORIA
Patients with non-valvular atrial fibrillation at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
CANTOS
Test the hypothesis that treatment with canakinumab will prevent recurrent cardiovascular events.
PARAGON
Compare a new agent, LCZ696, to valsartan in reducing the rate of cardiovascular death and heart failure hospitalizations, in heart failure patients with preserved ejection fraction (left ventricular ejection fraction ≥45%)
Insurance
Valley Medical Group providers accept the following plans.
Patient Ratings & Comments
Comments are gathered from our patient satisfaction surveys.